Holen Sie sich die Stockscreener-App
28.00
0.18%
0.05
Handel nachbörslich:
28.00
Schlusskurs vom Vortag:
$27.95
Offen:
$27.81
24-Stunden-Volumen:
728.54K
Relative Volume:
1.03
Marktkapitalisierung:
$1.26B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-80.50M
KGV:
-11.70
EPS:
-2.3936
Netto-Cashflow:
$-78.91M
1W Leistung:
-8.35%
1M Leistung:
-26.49%
6M Leistung:
+158.54%
1J Leistung:
+224.45%
1-Tages-Spanne:
$26.42
$28.99
1-Wochen-Bereich:
$26.42
$30.53
52-Wochen-Spanne:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
28.00 | 1.26B | 0 | -80.50M | -78.91M | -2.3936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Citizens reiterates Market Outperform on MBX Biosciences stock - Investing.com
Decoding MBX Biosciences Inc (MBX): A Strategic SWOT Insight - GuruFocus
Cowen Maintains Buy on MBX Biosciences, Inc. Common Stock (MBX) Mar 2026 - Meyka
Truist reiterates Buy on MBX Biosciences stock, $50 target - Investing.com Nigeria
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target - Investing.com UK
Stifel reiterates Buy rating on MBX Biosciences stock, $50 target By Investing.com - Investing.com UK
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III By Investing.com - Investing.com Australia
TD Cowen reiterates Buy on MBX Biosciences stock ahead of Phase III - Investing.com
Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights - Bitget
MBX: Advanced clinical pipeline and raised capital, supporting operations into 2029 - TradingView
MBX Biosciences 10-K: Operating loss $98.1M, Net loss $87.0M — cash runway into 2029 - TradingView
MBX: Phase 3 for hypoparathyroidism starts in Q3, with major obesity and PBH data readouts ahead - TradingView
Is MBX Biosciences’ (MBX) Regulatory Win and Leadership Refresh Reframing Its Hypoparathyroidism Strategy? - simplywall.st
Executives to engage with investors at key biotech events, MBX Biosciences outlines - Traders Union
MBX: FDA-aligned phase 3, strong pipeline, and funding secured for long-acting endocrine therapies - TradingView
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer - BioSpace
MBX Biosciences (NASDAQ:MBX) Stock Price Down 7.3%What's Next? - MarketBeat
MBX Biosciences to Initiate Phase 3 Trial of Once-Weekly Canvuparatide for Hypoparathyroidism Following Successful FDA End-of-Phase 2 Meeting - Minichart
MBX Biosciences completes FDA meeting for Phase 3 trial design By Investing.com - Investing.com South Africa
MBX Biosciences completes FDA meeting for Phase 3 trial design - Investing.com India
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - The Manila Times
Truist reiterates MBX Biosciences stock rating after FDA meeting By Investing.com - Investing.com Canada
Weekly hypoparathyroidism drug set for 2026 Phase 3 after FDA talks - Stock Titan
Truist reiterates MBX Biosciences stock rating after FDA meeting - Investing.com Australia
MBX Biosciences Advances Canvuparatide After Phase 2 FDA Meeting - TipRanks
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism - Bitget
MBX Biosciences, Inc. completes End-of-Phase 2 FDA meeting for chronic hypoparathyroidism therapy - Traders Union
MBX Biosciences to start Phase 3 trial for once-weekly canvuparatide in Q3 2026 after successful FDA EOP2 - TradingView
Weekly drug for hormone disorder heads to 160-patient trial - Stock Titan
MBX Biosciences CFO Shift Puts Funding And Execution In Focus - Yahoo Finance
Assessing MBX Biosciences (MBX) Valuation After Strong One Year Return And Recent Share Price Weakness - Sahm
MBX Biosciences CEO and CMO join key investor events at Citizens Bank conference and UBS Biotech Summit - Traders Union
TD Asset Management Inc Lowers Position in MBX Biosciences, Inc. $MBX - MarketBeat
Loss Report: Is MBX Biosciences Inc benefiting from interest rate changesTrend Reversal & Technical Buy Zone Confirmations - baoquankhu1.vn
MBX Biosciences annonce une offre d'actions après un doublement de l'action - TradingView
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MBX: Phase III and obesity data milestones, robust pipeline, and strong cash position drive outlook - TradingView
MBX: Clinically validated platform and robust pipeline drive multiple catalysts and strong financial outlook - TradingView
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Tech Rally: Is MBX Biosciences Inc benefiting from interest rate changesQuarterly Portfolio Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway - Yahoo Finance
MBX Biosciences, Inc. (MBX) Stock Report: Analyzing a 74% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
MBX Biosciences (MBX) CEO exercises stock options into 28,768 shares - Stock Titan
MBX Biosciences announces CFO transition and new lease for Massachusetts facility - Investing.com Australia
MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief - marketscreener.com
MBX Biosciences Announces CFO Transition and Interim Appointment - TipRanks
MBX appoints John Smither as Interim CFO as Richard Bartram to resign - TradingView
MBX Biosciences (Nasdaq: MBX) adds Burlington lab, names interim CFO - Stock Titan
MBX Biosciences, Inc. Announces CFO Changes - marketscreener.com
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):